Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) Operating Income (2019 - 2025)

Historic Operating Income for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to -$83.1 million.

  • Nurix Therapeutics' Operating Income fell 2851.66% to -$83.1 million in Q4 2025 from the same period last year, while for Nov 2025 it was -$285.7 million, marking a year-over-year decrease of 3409.85%. This contributed to the annual value of -$285.7 million for FY2025, which is 3409.85% down from last year.
  • Per Nurix Therapeutics' latest filing, its Operating Income stood at -$83.1 million for Q4 2025, which was down 2851.66% from -$91.4 million recorded in Q3 2025.
  • Over the past 5 years, Nurix Therapeutics' Operating Income peaked at -$24.5 million during Q1 2021, and registered a low of -$91.4 million during Q3 2025.
  • For the 5-year period, Nurix Therapeutics' Operating Income averaged around -$47.8 million, with its median value being -$45.5 million (2022).
  • Its Operating Income has fluctuated over the past 5 years, first tumbled by 9965.23% in 2021, then surged by 4145.25% in 2023.
  • Quarter analysis of 5 years shows Nurix Therapeutics' Operating Income stood at -$38.0 million in 2021, then decreased by 28.29% to -$48.7 million in 2022, then rose by 6.89% to -$45.3 million in 2023, then tumbled by 42.62% to -$64.7 million in 2024, then decreased by 28.52% to -$83.1 million in 2025.
  • Its last three reported values are -$83.1 million in Q4 2025, -$91.4 million for Q3 2025, and -$48.3 million during Q2 2025.